New CMS Rule Unlikely to Speed Medicare Coverage of Breakthrough Devices
The recently proposed TCET rule appears to be too stringent to significantly hasten the Medicare coverage process for device makers.
New CMS TCET Rule Likely Won’t Hasten Medicare Coverage of Breakthrough Devices
Recently proposed rule seems too stringent to reduce the lag between FDA approval and Medicare coverage.
Medicare Expands Coverage of Molecular Cancer Screening Tests
In terms of Medicare coverage, 2023 is shaping up to be a fruitful year—here are five of the most significant approvals so far.
Bill Would Require Medicare to Cover New Breakthrough Devices for at Least 4 Years
The bill is designed to provide Medicare patients faster access to innovative technology approved by the FDA.
Do Those on Medicare Advantage Receive Better Care?
Study shows that those enrolled in Medicare Advantage have lower rates of “low-value care” than those enrolled in traditional Medicare.